BR112022002954A2 - Composição farmacêutica, método para obter uma rhepo, e, uso da composição farmacêutica - Google Patents
Composição farmacêutica, método para obter uma rhepo, e, uso da composição farmacêuticaInfo
- Publication number
- BR112022002954A2 BR112022002954A2 BR112022002954A BR112022002954A BR112022002954A2 BR 112022002954 A2 BR112022002954 A2 BR 112022002954A2 BR 112022002954 A BR112022002954 A BR 112022002954A BR 112022002954 A BR112022002954 A BR 112022002954A BR 112022002954 A2 BR112022002954 A2 BR 112022002954A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- obtaining
- represent
- rhepo
- glycans
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
composição farmacêutica, método para obter uma rhepo, e, uso da composição farmacêutica. a presente invenção refere-se aos campos de biotecnologia e medicina e descreve uma composição farmacêutica de eritropoietina humana recombinante possuindo uma micro-heterogeneidade de n-glicanos fucosilados formados por estruturas bi, tri e tetra-antenárias com resíduos de ácido siálico mono e bissialilados que representam 40-60% do total de glicanos, trissialilados que representam 40-43% do total de glicanos e tetrassialilados que representam 10-13% do total de glicanos. este padrão de glicosilação confere propriedades à referida composição que permitem a sua utilização em distúrbios do sistema nervoso. a invenção também se refere ao método de obtenção da referida composição farmacêutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2019000077A CU24704B1 (es) | 2019-09-05 | 2019-09-05 | Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso |
| PCT/CU2020/050001 WO2021043345A1 (es) | 2019-09-05 | 2020-02-19 | Eritropoyetina humana recombinante hiposialilada, métodos de purificación y usos terapéuticos de esta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022002954A2 true BR112022002954A2 (pt) | 2022-05-17 |
Family
ID=72242895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022002954A BR112022002954A2 (pt) | 2019-09-05 | 2020-02-19 | Composição farmacêutica, método para obter uma rhepo, e, uso da composição farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220305084A1 (pt) |
| EP (1) | EP4026555A1 (pt) |
| JP (1) | JP2022546837A (pt) |
| KR (1) | KR20220057553A (pt) |
| CN (1) | CN114340653B (pt) |
| AR (1) | AR119839A1 (pt) |
| AU (1) | AU2020342140B2 (pt) |
| BR (1) | BR112022002954A2 (pt) |
| CA (1) | CA3150952A1 (pt) |
| CO (1) | CO2022002934A2 (pt) |
| CU (1) | CU24704B1 (pt) |
| MX (1) | MX2022002765A (pt) |
| TW (1) | TW202114729A (pt) |
| WO (1) | WO2021043345A1 (pt) |
| ZA (1) | ZA202203661B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024094457A1 (en) * | 2022-11-02 | 2024-05-10 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991005867A1 (en) * | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| CA2491567A1 (en) * | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| RU2370276C2 (ru) * | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
| CN101090973B (zh) * | 2004-12-30 | 2012-03-28 | 克鲁塞尔荷兰公司 | 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质 |
| CU23317A1 (es) | 2005-07-22 | 2008-10-22 | Ct De Investigacia N Y Desarro | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
| CN101448852A (zh) * | 2005-12-20 | 2009-06-03 | 布里斯托尔—迈尔斯斯奎布公司 | 组合物和用于生产组合物的方法 |
| JP5424871B2 (ja) * | 2006-05-19 | 2014-02-26 | グライコフィ， インコーポレイテッド | 組換えベクター |
| KR101847169B1 (ko) * | 2015-10-07 | 2018-04-09 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
| US11667686B2 (en) * | 2017-06-06 | 2023-06-06 | Kindred Biosciences, Inc. | Erythropoietin and analogs for veterinary use |
-
2019
- 2019-09-05 CU CU2019000077A patent/CU24704B1/es unknown
-
2020
- 2020-02-19 BR BR112022002954A patent/BR112022002954A2/pt unknown
- 2020-02-19 MX MX2022002765A patent/MX2022002765A/es unknown
- 2020-02-19 EP EP20761739.0A patent/EP4026555A1/en active Pending
- 2020-02-19 US US17/640,133 patent/US20220305084A1/en active Pending
- 2020-02-19 KR KR1020227009984A patent/KR20220057553A/ko active Search and Examination
- 2020-02-19 AU AU2020342140A patent/AU2020342140B2/en active Active
- 2020-02-19 CA CA3150952A patent/CA3150952A1/en active Pending
- 2020-02-19 CN CN202080062079.4A patent/CN114340653B/zh active Active
- 2020-02-19 WO PCT/CU2020/050001 patent/WO2021043345A1/es unknown
- 2020-02-19 JP JP2022514643A patent/JP2022546837A/ja active Pending
- 2020-08-26 AR ARP200102407A patent/AR119839A1/es unknown
- 2020-08-26 TW TW109129058A patent/TW202114729A/zh unknown
-
2022
- 2022-03-15 CO CONC2022/0002934A patent/CO2022002934A2/es unknown
- 2022-03-30 ZA ZA2022/03661A patent/ZA202203661B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114340653A (zh) | 2022-04-12 |
| CO2022002934A2 (es) | 2022-04-19 |
| AR119839A1 (es) | 2022-01-12 |
| AU2020342140B2 (en) | 2024-05-02 |
| CU24704B1 (es) | 2024-04-08 |
| CA3150952A1 (en) | 2021-03-11 |
| JP2022546837A (ja) | 2022-11-09 |
| CU20190077A7 (es) | 2021-04-07 |
| TW202114729A (zh) | 2021-04-16 |
| KR20220057553A (ko) | 2022-05-09 |
| AU2020342140A1 (en) | 2022-04-07 |
| US20220305084A1 (en) | 2022-09-29 |
| EP4026555A1 (en) | 2022-07-13 |
| MX2022002765A (es) | 2022-04-06 |
| WO2021043345A1 (es) | 2021-03-11 |
| ZA202203661B (en) | 2023-09-27 |
| CN114340653B (zh) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018005639A2 (pt) | profármacos de glicosídeo canabinoide e métodos de síntese | |
| BR112017021066A2 (pt) | glicosídeos de esteviol | |
| BR112017019170A2 (pt) | métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia | |
| BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
| BR112017025388A2 (pt) | plantas cannabis tendo expressão modificada de thca sintase | |
| BR112022002954A2 (pt) | Composição farmacêutica, método para obter uma rhepo, e, uso da composição farmacêutica | |
| BR112018010160A2 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
| BR112014012808A2 (pt) | proteína de fusão anticâncer | |
| BR112019001794A2 (pt) | composição de cannabis | |
| BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
| BR112017017530A2 (pt) | proteínas específicas para pioverdina e pioquelina | |
| BR112018000785A2 (pt) | estrutura de quadro e método de construção de estrutura de quadro | |
| BR112019016300A2 (pt) | ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO | |
| BR112014029645A2 (pt) | produto assado, molde para produzir um produto assado, método para produzir pelo menos um produto assado e método de fabricação de um produto de petisco | |
| BR112018002562A2 (pt) | transporte de glicosídeo de esteviol | |
| BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
| BR112018010887A2 (pt) | polipeptídeo de fusão | |
| BR112017009545B8 (pt) | Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária | |
| BR112019004488A2 (pt) | composições compreendendo triterpenoides e utilizações das mesmas para tratamento de neuropatia ótica | |
| BR112017019469A2 (pt) | processo para produzir um extrato de matriz vegetal por extrusão com uma solução hidrotrópica | |
| BR112018069033A2 (pt) | guia de luz com estruturas de desvio de luz | |
| BR112015030697A2 (pt) | Vacina semiviva contra o vírus sincicial respiratório | |
| BR112018014525A2 (pt) | compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos | |
| BR112016008086A2 (pt) | Glicoproteínas recombinantes e usos das mesmas | |
| BR112017013650A2 (pt) | processo e concentrado para a fabricação de uma pré-mistura |